Skip to content

Transplantation of Autologous Oral Mucosal Epithelial Stem Cell Sheet for Treating Limbal Stem Cell Deficiency Disease

Transplantation of Autologous Oral Mucosal Epithelial Stem Cell Sheet for Treating Limbal Stem Cell Deficiency Disease

Status
UNKNOWN
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03015779
Enrollment
7
Registered
2017-01-10
Start date
2017-01-31
Completion date
2018-12-31
Last updated
2017-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Limbal Stem Cell Deficiency

Brief summary

The aim of this trials investigates the therapeutic effects of application autologous oral mucosal epithelial cell sheets in the treatment of limbal stem cell deficiency disease.

Detailed description

A number of external factors can result in limbal stem cell deficiency(LSCD), causing pain, pathological corneal epithelium regeneration, inflammation reaction and seriously visual loss. For patients with unilaterally damaged eye, transplantation of limbal tissue from the healthy eye can be used in the past years in the risk of inducing limbal stem cell damaged in the healthy eye. While graft of human leukocyte antigen matched allogenic limbal stem cells require immune suppressive medications, it can cause side effects in the body. Over the past 10 years, the clinical trials of application of cultured autologous oral mucosal epithelial cell sheet to treat LSCD have been emerged as a promising strategy in many countries. However, little study has been reported in China. This study investigates the therapeutic effects of application autologous oral mucosal epithelial cell sheets in the treatment of limbal stem cell deficiency disease in China.

Interventions

OTHERcultured autologous oral mucosal epithelial cell sheet

a prospective study,Before and after self control

Sponsors

He Eye Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Male or female aged\>=18 years old * Normal intraocular pressure * Normal Eyelid * No cataract and retinal disease * No ulcers and tumor in the mouth

Exclusion criteria

* Severe Systemic infection * History of acute phase of ocular and oral inflammation * History of hyper sensibility or allergy to antibiotics or serum * Women who are or may be pregnant * Patients with infectious diseases * Patients with other complications

Design outcomes

Primary

MeasureTime frameDescription
The area of reepithelialization of corneal epithelium3 monthsThe preoperative status of the eye will be recorded on the basis of clinical drawings and pre-and post-operative photographs. These pictures will be sent to two corneal experts in order to evaluate the results. Judgement criterion: the results will be tested with a slit lamp: Normal: no epithelial loss; Mild: the area of epithelial loss \<1/3; Moderate: the area of epithelial loss \>1/3 \<2/3; Severe: the area of epithelial loss\> 2/3

Secondary

MeasureTime frame
Improvement of best correct visual acuityone year
Decrease of corneal neovascularizationone year

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026